Antares Pharma Inc. (ATRS)

3.30
NASDAQ : Health Technology
Prev Close 3.30
Day Low/High 3.25 / 3.48
52 Wk Low/High 2.53 / 3.96
Avg Volume 1.08M
Exchange NASDAQ
Shares Outstanding 163.06M
Market Cap 538.10M
P/E Ratio N/A
Div & Yield N.A. (N.A)
Antares Pharma Announces Additional Patent Coverage For OTREXUP

Antares Pharma Announces Additional Patent Coverage For OTREXUP

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.

Antares Pharma Inc. Stock Downgraded (ATRS)

Antares Pharma Inc. Stock Downgraded (ATRS)

Antares Pharma (Nasdaq:ATRS) has been downgraded by TheStreet Ratings from from a hold to sell.

Ratings Changes Today

Upgrades: CLMS, DNR, GBX, ORRF, PPSI, TCPC, YDKN Downgrades: ATRS, EXK, MGLN, PERY, SBS, SPPI, VICR Initiations: ALQA, CRRS, FNRG, ICLD, LBMH, PFIE, XXII, ZTS Read on to get TheStreet Quant Ratings' detailed report:

Interesting ATRS Put And Call Options For November 22nd

Interesting ATRS Put And Call Options For November 22nd

Investors in Antares Pharma Inc. saw new options become available this week, for the November 22nd expiration.

Antares Pharma Reports Fourth Quarter And Full Year 2013 Operating And Financial Results

Antares Pharma Reports Fourth Quarter And Full Year 2013 Operating And Financial Results

Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the fourth quarter and full year ended December 31, 2013.

Antares Pharma Receives Second Milestone Payment From LEO Pharma In OTREXUP Collaboration

Antares Pharma Receives Second Milestone Payment From LEO Pharma In OTREXUP Collaboration

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the receipt of a second milestone payment of $5 million from LEO Pharma.

Antares Pharma Announces LEO Pharma’s Launch Of OTREXUP (Methotrexate) Injection To Dermatologists For Adults With Psoriasis

Antares Pharma Announces LEO Pharma’s Launch Of OTREXUP (Methotrexate) Injection To Dermatologists For Adults With Psoriasis

Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma’s launch of OTREXUP to Dermatologists, the first U.

Antares Pharma To Host Fourth Quarter 2013 Operating And Financial Results Conference Call

Antares Pharma To Host Fourth Quarter 2013 Operating And Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2013 financial results before the market opens on Thursday, March 13, 2014, and host a conference call shortly thereafter at 8:30 a.

First Week Of ATRS April 19th Options Trading

First Week Of ATRS April 19th Options Trading

Investors in Antares Pharma Inc. saw new options become available this week, for the April 19th expiration.

Antares Pharma To Present At The Cowen And Company 34th Annual Healthcare Conference

Antares Pharma To Present At The Cowen And Company 34th Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

Antares Pharma Announces Positive Results From The VIBEX QuickShot Pharmacokinetic Study In Testosterone Deficient Men

Antares Pharma Announces Positive Results From The VIBEX QuickShot Pharmacokinetic Study In Testosterone Deficient Men

Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone enanthate administered once-weekly by subcutaneous...

Antares Pharma To Participate In The 2014 RBC Capital Markets’ Global Healthcare Conference

Antares Pharma To Participate In The 2014 RBC Capital Markets’ Global Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that LeRoux Jooste, Senior Vice President and General Manager Pharmaceuticals, will participate in the RBC Capital Markets’ Global Healthcare Conference on ...

Interesting ATRS Call Options For March 22nd

Interesting ATRS Call Options For March 22nd

Investors in Antares Pharma Inc. saw new options become available this week, for the March 22nd expiration.

Interesting ATRS Call Options For January 18th

Interesting ATRS Call Options For January 18th

Investors in Antares Pharma Inc. saw new options become available this week, for the January 18th expiration.

Antares Pharma To Present At The 32nd Annual J.P. Morgan Healthcare Conference

Antares Pharma To Present At The 32nd Annual J.P. Morgan Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

Antares Pharma (ATRS) Shares Cross Below 200 DMA

Antares Pharma (ATRS) Shares Cross Below 200 DMA

In trading on Friday, shares of Antares Pharma Inc. crossed below their 200 day moving average of $4.07, changing hands as low as $4.02 per share.

First Week of August 2014 Options Trading For Antares Pharma (ATRS)

First Week of August 2014 Options Trading For Antares Pharma (ATRS)

Investors in Antares Pharma Inc. saw new options become available this week, for the August 2014 expiration.

Antares Pharma® Announces Notice Of Allowance For New Patent On Reconstitutable Lyophilized Injectables

Antares Pharma® Announces Notice Of Allowance For New Patent On Reconstitutable Lyophilized Injectables

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Allowance from the U.

Antares Pharma To Present At The Oppenheimer 24th Annual Healthcare Conference

Antares Pharma To Present At The Oppenheimer 24th Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

Antares Pharma Announces Additional U.S. Patent Protection For OTREXUP™

Antares Pharma Announces Additional U.S. Patent Protection For OTREXUP™

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.

Antares Pharma Appoints David H. Bergstrom Ph.D. As Senior Vice President Pharmaceutical Development

Antares Pharma Appoints David H. Bergstrom Ph.D. As Senior Vice President Pharmaceutical Development

Antares Pharma, Inc. (NASDAQ:ATRS) today announced the appointment of David H.

Antares Pharma To Present At The Jefferies 2013 Global Healthcare Conference

Antares Pharma To Present At The Jefferies 2013 Global Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

Antares Pharma Enters Into An Exclusive U.S. Promotion And Marketing Agreement With LEO Pharma For OTREXUP™ In Dermatology

Antares Pharma Enters Into An Exclusive U.S. Promotion And Marketing Agreement With LEO Pharma For OTREXUP™ In Dermatology

Antares Pharma, Inc. (NASDAQ: ATRS) today announced an exclusive promotion and marketing agreement with LEO Pharma for detailing OTREXUP ™ (methotrexate) to dermatologists for symptomatic control of severe ...

Antares Pharma Reports Third Quarter 2013 Operating And Financial Results

Antares Pharma Reports Third Quarter 2013 Operating And Financial Results

Antares Pharma, Inc. (NASDAQ:ATRS) today reported operating and financial results for the third quarter ended September 30, 2013.

Antares Pharma Appoints Dr. Bruce Freundlich As Senior Vice President

Antares Pharma Appoints Dr. Bruce Freundlich As Senior Vice President

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr.

Antares Pharma To Host Third Quarter 2013 Operating And Financial Results Conference Call

Antares Pharma To Host Third Quarter 2013 Operating And Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2013 financial results before the market opens on Wednesday, November 6, 2013, and host a conference call shortly thereafter at 8:30...

Antares Pharma Announces The Issuance Of A New U.S. Patent On The VIBEX® Device Platform

Antares Pharma Announces The Issuance Of A New U.S. Patent On The VIBEX® Device Platform

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.

First Week Of ATRS December 21st Options Trading

First Week Of ATRS December 21st Options Trading

Investors in Antares Pharma Inc. saw new options begin trading this week, for the December 21st expiration.

Antares Announces Podium Presentation Of Pivotal OTREXUP™ (methotrexate) Data At American College Of Rheumatology Annual Meeting

Antares Announces Podium Presentation Of Pivotal OTREXUP™ (methotrexate) Data At American College Of Rheumatology Annual Meeting

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from a pivotal clinical trial of OTREXUP™ (methotrexate) for subcutaneous injection were selected for live, oral presentation during a clinical ...

TheStreet Quant Rating: C (Hold)